Objectives: Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases.
Methods: We studied effects of amlodipine, atorvastatin, and their combination on carotid arteriosclerotic processes in a metabolic syndrome model of Zucker fatty rats. Zucker fatty rats were treated with vehicle, amlodipine, atorvastatin, or combination amlodipine plus atorvastatin for 28 days.
Results: Compared with the single treatment with amlodipine or atorvastatin, the combination of amlodipine plus atorvastatin treatment prevented arteriosclerotic processes, and induced a strong recovery of Sirtuin1 (Sirt1) expression and a marked reduction in p53, p21, and monocyte chemoattractant protein-1 (MCP-1).
Discussion: As Sirt1 is a longevity gene that prevents endothelial atherosclerotic processes, and p53, p21, and MCP-1 play pivotal roles in the initiation and development of atherosclerosis, these data suggest a strong synergistic benefit of combination therapy with amlodipine and atorvastatin for preventing atherosclerotic processes, and potentially reducing the clinical risk of cerebrovascular events in metabolic obesity patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1179/1743132812Y.0000000131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis.
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Institute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany.
For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022.
View Article and Find Full Text PDFPhase 1 Evaluation of the Bioequivalence and Drug-Drug Interaction Potential of a Novel Fixed-Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine.
Clin Pharmacol Drug Dev
December 2024
Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea.
Article Synopsis
- A new fixed-dose combination of ezetimibe, atorvastatin, and amlodipine has been created to help patients with cardiovascular diseases stick to their medication.
- In a study with 34 participants, it was found that taking this combination with amlodipine didn't significantly change how the drugs behave in the body, although amlodipine did slightly increase atorvastatin levels by about 23%.
- Another study with 60 participants confirmed that the combination formulation works similarly to taking each drug separately, showing that it is bioequivalent and just as well tolerated.
Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants.
Adv Ther
July 2024
Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
Introduction: Fixed-dose combinations (FDCs) of angiotensin II receptor blockers, calcium channel blockers, and statins are conventional therapeutic interventions prescribed for cardiovascular diseases. This study aimed at drawing a comparison between the pharmacokinetics and safety of an FDC and the corresponding individual formulations in healthy subjects.
Methods: A randomized, open-label, single-dose, three-sequence, three-period, partially repeated crossover study was conducted with a cohort of healthy volunteers.
Clinical Benefit of Fixed-Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia.
J Am Heart Assoc
May 2024
Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan.
Article Synopsis
- Hypertension and hypercholesterolemia are major risk factors for cardiovascular disease, and fixed-dose combination (FDC) treatments are recommended, but their clinical outcomes at different dosages are not well understood.
- This study analyzed the effects of different dosages of an FDC of amlodipine and atorvastatin on cardiovascular outcomes in over 9,000 patients, focusing on composite cardiovascular events.
- Results showed that the high-dose FDC (5 mg amlodipine and 20 mg atorvastatin) significantly reduced the risk of cardiovascular complications compared to a lower-dose FDC and a free combination treatment.
A Case of Omeprazole-Associated Acute Interstitial Nephritis.
Cureus
February 2024
Internal Medicine, Tower Health Medical Group, Reading, USA.
Acute interstitial nephritis (AIN) is characterized by an inflammatory infiltrate of the interstitium of the kidney, typically causing a decline in kidney function. Drug-induced AIN (also called allergic AIN) is a type of AIN. Common drugs associated with AIN are antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), and proton pump inhibitors (PPIs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!